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The antiviral activity of UV-4 was previously demonstrated against dengue virus serotype 2 (DENV2) in
multiple mouse models. Herein, step-wise minimal effective dose and therapeutic window of efﬁcacy
studies of UV-4B (UV-4 hydrochloride salt) were conducted in an antibody-dependent enhancement
(ADE) mouse model of severe DENV2 infection in AG129 mice lacking types I and II interferon receptors.
Signiﬁcant survival beneﬁt was demonstrated with 10e20 mg/kg of UV-4B administered thrice daily
(TID) for seven days with initiation of treatment up to 48 h after infection. UV-4B also reduced infectious
virus production in in vitro antiviral activity assays against all four DENV serotypes, including clinical
isolates. A set of puriﬁed enzyme, in vitro, and in vivo studies demonstrated that inhibition of endo-
plasmic reticulum (ER) a-glucosidases and not the glycosphingolipid pathway appears to be responsible
for the antiviral activity of UV-4B against DENV. Along with a comprehensive safety package, these andSpring Street, Silver Spring,
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Glucosidasepreviously published data provided support for an Investigational New Drug (IND) ﬁling and Phases 1
and 2 clinical trials for UV-4B with an indication of acute dengue disease.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Table 1
Summary of antiviral activity based on a virus yield reduction assay of UV-4B against
multiple dengue strains in Vero cells. To determine the IC50, UV-4B was pre-
incubated for 1 h, the cells were infected with the indicated dengue virus isolates for
1 h at MOI of 0.01 and the media replaced before a ﬁve day incubation period. The
supernatants were then assessed for functional virus using an immunoplaque assay.
Shown are the results for the individual experiments, each as the average of 2e4
replicates along with the calculated average and standard deviation (SD).
IC50 UV-4B [mM]a
Serotype Isolate Replicate Average SD
1 2 3 4
DENV-1 779,172b 0.47 3.52 8.52 8.08 5.15 3.85
SH29177b 3.86 0.33 e e 2.10 2.50
PRS41393 29.95 45.43 e e 37.69 10.95
DENV-2 SL 5-17-04b 7.42 9.91 41.09 30.96 22.34 16.36
NGCc 5.41 5.84 5.75 8.95 6.49 1.65
UIS 1288b 27.94 12.48 13.46 20.86 18.69 7.21
DENV-3 SL 5-29-04b 2.33 2.73 5.38 4.11 3.64 1.39
UIS 776b 8.55 4.58 8.55 4.58 6.56 2.80
H87 87.60 85.37 e e 86.49 1.58
DENV-4 779,157b 0.90 35.47 e e 18.18 24.44
C258/97b 9.83 8.06 e e 8.95 1.25
H241 2.78 1.42 e e 2.78 1.42
e Not performed.
a Data shown as IC50 are the results for the individual experiments, each as the
average of 2e3 replicates within each experiment.
b Clinical isolates were obtained from World Reference Center for Emerging Vi-
ruses and Arboviruses at University of Texas Medical Branch.
c Obtained from ATCC (Manassas, Virginia).1. Main text
Dengue virus (DENV) can cause a range of disease manifesta-
tions from asymptomatic infection to severe dengue disease, which
can result in death (Halstead, 2007). DENV is estimated to infect up
to 390 million people worldwide annually (Bhatt et al., 2013). The
resultant disease is a global health burden that strains medical
systems in tropical and subtropical regions, where the virus cir-
culates in Aedes mosquito populations. Currently no approved
vaccine or antiviral therapy for DENV exists (Coller et al., 2010;
Gubler, 1998; Julander et al., 2011). Four distinct serotypes of
DENV (designated DENV1-4) infect humans, and epidemiological
studies indicate that severe disease occurs most often during sec-
ondary infection with a heterologous serotype. A leading hypoth-
esis to explain this phenomenon, the antibody-dependent
enhancement (ADE) hypothesis, states that the presence of cross-
reactive, non-neutralizing antibodies generated during primary
infection or acquired passively at birth contributes to severe disease
upon infection by another serotype (Halstead, 2007).
Iminosugars have been explored as antiviral agents against
enveloped viruses because they demonstrate selective inhibition of
viral assembly and secretion, presumably through the inhibition of
the host endoplasmic reticulum (ER)-resident glycosylation
pathway, leading to misfolding of viral glycoproteins (Chang et al.,
2013; Durantel et al., 2005; Dwek et al., 2002; Mehta et al., 1998).
An antiviral agent that targets a host pathway could avoid chal-
lenges associated with directly acting antivirals, including viral
susceptibility, virus heterogeneity and the rapid emergence of
drug-resistant mutants (Sayce et al., 2010). We recently conducted
a study of DENV evolution under pressure with the host-targeted
iminosugar UV-4B, the hydrochloride salt of UV-4 (N-(90-methox-
ynonyl)-1-deoxynojirimycin or MON-DNJ). This study demon-
strated a high genetic barrier to escape mutations, supporting the
theory that host-targeted therapies should show signiﬁcantly
reduced likelihood for development of resistance-conferring mu-
tations (Plummer et al., 2015). We have previously characterized
the efﬁcacy of UV-4 and UV-4B in vivo in mouse models of severe
dengue disease via both direct infection (virus only) and ADE (virus
plus exogenous DENV-speciﬁc antibodies) studies. UV-4 protected
mice from lethal DENV infection in a dose-dependent manner,
reduced viral titer in tissues, and decreased cytokine levels in cir-
culation (Perry et al., 2013). We also showed that initiation of UV-4
treatment could be delayed until 48 h after infection when a high
dose was administered [100 mg/kg given thrice daily (TID)].
Importantly, administration of UV-4 did not alter antibody re-
sponses after DENV infection. Together, these ﬁndings supported
further investigation of UV-4B (the hydrochloride salt was selected
for development).
Previously, the in vitro activity of UV-4 was described against
DENV2 (Perry et al., 2013). In the current study, the antiviral activity
of UV-4 against DENV1-4 was assessed using an infectious virus
yield-reduction assay similar to previous reports (Warﬁeld et al.,
2015). Brieﬂy, UV-4B was tested for activity at 6e8 concentrations
(two-fold dilutions starting at 125e500 mM, each in duplicate) and
the collected supernatants were quantitated for functional DENV
using an immunoplaque assay. As shown in Table 1, UV-4B inhibi-
ted all the DENV isolates tested in vitro. The 50% inhibitory con-
centration (IC50) values for UV-4B in these studies ranged from
2.10 mM (DENV1 SH29177) to 86.49 mM (DENV3 H87). Theselectivity index, calculated from the IC50 and CC50 (50% cytotoxic
concentration) of UV-4 in Vero cells (CC50 > 1 mM), ranged from
>11.6 to >477. Using a similar assay set up in BHK cells, the IC50 of
UV-4B against the mouse challenge virus DENV-2 S221 was found
to be 38.98 mM.
In the in vivo studies described here, mice were dosed orally
with varying concentrations (100, 40, 20 or 10 mg/kg) of UV-4 TID
as aqueous UV-4B solution, starting 1 h before or 24 or 48 h after
lethal ADE DENV2 challenge (Plummer and Shresta, 2014; Tang
et al., 2015; Zellweger and Shresta, 2014), and every 8 h there-
after for a total of seven days of treatment. Weight loss and health
were monitored daily throughout infection and dosing, and
continued for three days following the dosing period to quantitate
changes in disease course. Health was determined on the basis of
clinical scores ranging from 1 (completely healthy) to 7 (dead),
based on a detailed rubric that includes evaluation of hunched
posture, rufﬂing of fur, inset of eyes, and lethargy as previously
described (Stavale et al., 2015). Based on extensive studies of this
mousemodel, animals that lost >20% of their original weight or had
a clinical score 5 were considered to have succumbed to dengue
disease and were euthanized immediately. Mice dosed with
100 mg/kg TID starting at 1, þ24, or þ48 h relative to infection
exhibited survival rates of 90, 90, and 100%, respectively (all p-
values <0.01 compared to vehicle treatment, Fig. 1). Similarly, an-
imals dosed with 40 mg/kg TID starting at 1, þ24, or þ48 h
relative to infection had survival rates of 100, 100, and 90%,
respectively (all p-values <0.01 compared to vehicle treatment,
Fig. 1). Animals dosed with 20 mg/kg TID starting at 1, þ24,
or þ48 h relative to infection had survival rates of 85, 100, and 70%,
respectively (all p-values <0.01 compared to vehicle treatment,
Fig. 1). Animals dosed with 10 mg/kg TID showed statistically
Fig. 1. Therapeutic window of various dose levels of UV-4B in lethal dengue ADE mouse model. Groups of AG129 mice (n ¼ 10) received the ﬁrst treatment dose of 100, 40, 20 or
10 mg/kg of UV-4 (dosed orally as UV-4B) or vehicle 1 h before or 24 or 48 h after infection with DENV2 S221 in the presence of DENV-speciﬁc antibody clone 2H2 at a dose of ~1
LD90 (109 genomic equivalents); treatment continued every 8 h daily for seven days once initiated. (Top row) Survival data are plotted as percent survival against days post-infection.
Asterisks denote statistical signiﬁcance as determined by the GehaneBresloweWilcoxon test (*, p ¼ 0.05; **, p ¼ 0.01; ***, P < 0.001). (Middle row) The mean percent weights for
each group are plotted compared to their percent weight on Day -1 (baseline) against days post-infection. Error bars represent the standard error mean (SEM). (Bottom row) The
mean health score, based on a standardized system with values from 1 to 7 given daily to each mouse, with the SEM for each group plotted against days post-infection.
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not þ48 h relative to infection, with survival rates of 60 (p < 0.01),
56 (p < 0.05), and 36% (p > 0.05), respectively (Fig. 1). The control
groups that were infected with the same lethal ADE DENV chal-
lenge but dosed TID with vehicle only (water) had 10e20% survival
(Fig. 1). Additionally, the control groups receiving vehicle only lost
signiﬁcantly moreweight and had signiﬁcantly worse health scores
as compared to animals dosed with UV-4B (data not shown). Under
the conditions of this study, signiﬁcant increases in survival were
observed when mice were dosed at 10 mg/kg TID with treatment
delayed for as long as 24 h post-infection; increased survival was
observed at the 20 mg/kg TID dose when treatment was delayed as
late as 48 h post-infection. In a separate experiment, reduction in
viral titers in serum and various tissues was demonstrated in a
slightly different ADE DENV2 model (Balsitis et al., 2010; Orozco
et al., 2012; Perry et al., 2013; Rathore et al., 2011; Schul et al.,
2007; Watanabe et al., 2012) when mice were treated with
100 mg/kg of UV-4 as UV-4B (Supplementary Figure 1).
The proposed antiviral mechanism of action of UV-4B is
competitive inhibition of ER-resident a-glucosidases I and II. The
potential utility of ER a-glucosidases as a pharmacological target
capable of conferring broad-spectrum resistance to viral infectivity
was demonstrated in a recent publication that characterized two
children with a genetic defect resulting in absence of ER a-gluco-
sidase I (Sadat et al., 2014). In spite of signiﬁcant hypogamma-
globulinemia, the children had no history of viral disease, were not
able to generate immune responses to live viral vaccines, and their
cells did not support replication of phylogenetically divergent vi-
ruses including HIV and inﬂuenza. To conﬁrm that pharmacological
inhibition of the ER a-glucosidases is the mechanism by which UV-
4B confers antiviral activity, puriﬁed enzyme, cellular, and animal
studies using UV-4B with a glucose (MON-DNJ, Fig. 2A) or galactose
(N-(90-methoxynonyl)-1,6-dideoxygalactonojirimycin (MON-6-
deoxy-DGJ or MON-6d-DGJ, Fig. 2B)) sterochemistry were con-
ducted. Differences in inhibition of glucosidase and glycosidaseenzymes speciﬁc to sugar stereochemistries (glucose versus
galactose) may exist and affect their antiviral activities.
First, human monocyte-derived macrophages (MDMFs) from a
minimum of three donors were infected with DENV2 strain 16681
and then incubated for 48 h in the presence of serial dilutions of
UV-4B (MON-DNJ) or MON-6d-DGJ. Infectious virus was quanti-
tated by plaque assay, and only the glucomimetic UV-4B inhibited
DENV2 replication (Fig. 2C). The effect on total virus production by
UV-4Bwas then assessed by quantitative reverse transcriptase real-
time polymerase chain reaction (qRT-PCR) for DENV NS5 RNA and
compared with functional virus load quantitated by plaque assay
(Fig. 2D) (Laue et al., 1999; Sayce et al., 2015). Inhibition of infec-
tious (functional) viral titer correlated directly with decrease in
total virus secreted (Fig. 2D).
Next, the proﬁle of inhibition of puriﬁed glucosidases and gly-
cosidases by UV-4B and MON-6d-DGJ, respectively, was tested as
previously described (Asano et al., 1998; Sayce et al., 2015). As
shown in Table 2, UV-4B demonstrated inhibition of puriﬁed ER a-
glucosidases I and II with IC50 of 0.16 and 1.8 mM, respectively, while
MON-6d-DGJ did not inhibit these enzymes up to the highest
concentration tested (1.05 mM). Similar observations were made
for both molecules regarding inhibition of other a-glucosidases.
Conversely, as expected, only MON-6d-DGJ inhibited a-galactosi-
dase (Table 2). UV-4B appears to be a more potent inhibitor of
ceramide glucosyltransferase isolated from the human cell line
HL60 than MON-6d-DGJ (IC50 of 0.39 and 88.3 mM, respectively).
Neither molecule was a strong inhibitor of enzymes responsible for
processing b-linkages or non-glucose, non-galactose containing
saccharides (data not shown).
Further analyses of the enzymatic activities of the molecules in
MDMFs were undertaken in the absence of DENV infection by
detecting glycosphingolipids (GSLs) and free oligosaccharides (FOS)
as previously described (Alonzi et al., 2008; Neville et al., 2004).
First, MDMFs were treated for 48 h with 100 mM of UV-4B or
105 mM of MON-6d-DGJ, and whole cell lysates were collected and
Fig. 2. In vitro evaluation of iminosugar enzyme inhibition and antiviral activity using human monocyte-derived macrophages (MDMFs). Chemical structure of (A) N-(90-
methoxynonyl)-1-deoxynojirimycin hydrochloride (UV-4B, MON-DNJ) and (B) N-(90-methoxynonyl)-1,6-dideoxygalactonojirimycin (MON-6d-DGJ). (C-D) Primary human MDMFs
were infected with DENV2 strain 16681 at a multiplicity of infection of 1 and treated with a titration of iminosugar for 48 h. (C) Infectious virus titer was determined by plaque assay
using LLC-MK2 (monkey kidney) cells. Cells from three donors were treated in triplicate and resulting samples quantitated using plaque assays in triplicate on each sample. Counts
were normalized to 100% for untreated samples. Data are presented as mean ± SD. (D) Production of functional virus (quantitated using LLC-MK2 plaque assays) conducted on nine
technical replicates was compared to total virus secreted (assessed using qRT-PCR conducted in technical duplicate) in untreated cells or cells treated with UV-4B. The values for
both RNA and infectious virus are means normalized to untreated samples within a donor and a single representative donor is plotted as mean ± SD. (E) Uninfected human MDMFs
were treated with iminosugars for 48 h and glycolipids were isolated from whole cell lysates. Production of monosialodihexosylganglioside (GM3) was normalized to total protein
content for each sample and each treatment was normalized to untreated controls on a donor speciﬁc basis. Inhibition of GM3 production by 100 mM of UV-4B (black) or 105 mM of
MON-6d-DGJ (red) was assessed (inset) and a range of UV-4B concentrations. Data are presented as mean ± SD from assay of three biological replicates assayed in single sample. (F)
MDMFs were treated in technical duplicate for 48 h with iminosugar with a serial dilution of UV-4B or MON-6d-DGJ (not shown, results were negative) and inhibition of a-
glucosidase I was measured by accumulation of Glc3Man5GlcNAc1 (white circles) while inhibition of a-glucosidase II was measured by accumulation of Glc1Man4GlcNAc1 (black
circles). For each donor, the maximal concentration of each oligosaccharide species reached was normalized to 100%.
Table 2
In vitro enzyme inhibition by iminosugars.
Class Enzyme IC50a
UV-4B MON-6d-DGJ
a-glucosidase Mouse ER a-glucosidase I 0.16 mM >1.05 mMb
Mouse ER a-glucosidase II 1.8 mM >1.05 mMb
Rat intestinal maltase 0.28 mM >1.05 mMb
Rat intestinal isomaltase 1.4 mM >1.05 mMb
Rat intestinal sucrase 0.5 mM >1.05 mMb
Human lysosome 0.39 mM >1.05 mMb
Glucosyltransferase HL60c 0.39 mM 88.26 mM
a-galactosidase Human lysosome >1 mMb 255.8 mM
a IC50 is the concentration required to inhibit the enzyme to 50% activity.
b The drug did not reach an IC50 for the given enzyme up to the maximal dose
tested.
c HL60 is a human promyelocytic cell line fromwhich the glucosyltransferase has
been isolated.
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dicator for modiﬁcation of glycolipid processing (Platt et al., 1994a,
1994b). As shown in the inset graph in Fig. 2E, UV-4B and MON-6d-
DGJ both reduced GM3 levels (normalized to total protein) by>90%.
The dose-dependent relationship of UV-4B on GM3 levels was
demonstrated in cells from three donors over a titration of
1e100 mM (Fig. 2E). The lowest dose tested (1 mM) reduced GMS3
levels by an average of 73% and >90% inhibition was observed with
10 mMUV-4B. Generation of FOS is used as a marker of inhibition of
ER-resident a-glucosidases and has been previously used in
immortalized cell lines and rodents (Alonzi et al., 2008). The gen-
eration of FOS was assessed in the MDMFs after 48 h of treatment
with 100 mM of UV-4B or 105 mM of MON-6d-DGJ. FOS that were
detected in MON-6d-DGJ treated samples were identiﬁed as FOS
generated by inhibition of lysosomal b-N-acetylhexosaminidases
(Glawar et al., 2012), while monoglucosylated or triglucosylated
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glycoprotein processing, were not detected (data not shown). In
contrast, addition of 100 mM of UV-4B led to accumulation of FOS
representative of inhibition of both a-glucosidases, and the full
dose-response relationship of treatment with UV-4B and produc-
tion of FOS is shown in Fig. 2F.
Lastly, protection in the DENV ADE mouse model was compared
after seven days of treatment with 100 mg/kg TID of UV-4 as UV-4B
or the same dose and regimen of MON-6d-DGJ. The results clearly
showed antiviral efﬁcacy of UV-4B (p < 0.0001) but not MON-6d-
DGJ (Fig. 3). Together, these ﬁndings suggest that antiviral activity
of UV-4B is mediated by the inhibition of the ER a-glucosidases and
not via inhibition of the glycosphingolipid pathway, which is
inhibited by both UV-4B and MON-6d-DGJ. These data support and
extend the ER a-glucosidases mechanism of action demonstrated
for related glucose- and galactose-stereochemistry iminosugars
(Sayce et al., 2015).
Our previous studies demonstrated the iminosugar UV-4 and its
hydrochloride salt UV-4B are protective against lethal DENV2
challenge and reduce viremia and viral titers in multiple tissues
(Perry et al., 2013). Additionally, we demonstrated there is no evi-
dence of escape of DENV via resistance-conferring mutation after
multiple passages in mice in the presence of UV-4B (Plummer et al.,
2015), and that treatment with UV-4B does not alter the antibody
response after DENV infection (Perry et al., 2013). The in vivo
studies described herein were conducted to further deﬁne the
minimum effective dose and the therapeutic window for oral
dosing of UV-4B in the same ADE model of DENV infection, for the
purpose of informing decisions about proposed dosing regimens
for future human clinical trials. The effective oral dose of UV-4BFig. 3. Antiviral efﬁcacy of UV-4B and MON-6d-DGJ in lethal dengue ADE mouse
model. Groups (n ¼ 10) of male and female AG129 mice, aged 5 weeks, received the
ﬁrst treatment dose of 100 mg/kg of UV-4B and MON-6d-DGJ compound or vehicle
(water) orally starting 1 h before infection with DENV2 S221 and administration of
DENV-speciﬁc antibody clone 2H2 at a dose of ~1 LD90 (109 genomic equivalents);
treatment with UV-4B continued every 8 h daily for 7 days. (Top) Survival data are
plotted as percent survival against days post-infection. Asterisks denote statistical
signiﬁcance as determined by the Log-rank (Mantel-Cox) test (***P < 0.001). (Bottom)
The mean percent weights for each group are plotted compared to their percent
weight on Day -1 against days post-infection. Error bars represent the standard error
mean (SEM).given TID for seven days that resulted in statistically signiﬁcant
survival was considered to be 10 mg/kg and 20 mg/kg, when
administrationwas initiated 24 or 48 h after infection, respectively.
Additionally, we demonstrated efﬁcacy against a diverse set of
DENV1-4 clinical isolates in vitro. The UV-4B IC50 for the mouse
challenge virus S221 is on the higher end and two-fold above the
average in vitro IC50 (~20uM) of the other 12 isolates (Table 1);
therefore, we predict the S221 mouse model is more, rather than
less, stringent for assessing the antiviral activity of UV-4B in vivo.
Further, the studies here conﬁrm that ER a-glucosidase inhibition
and not inhibition of glycolipid processing is likely responsible for
the antiviral activity of the iminosugar UV-4B. These studies sup-
port the clinical development of UV-4B in ongoing Phase 1 (https://
clinicaltrials.gov/ct2/show/NCT02061358) and planned Phase 2
clinical trials.
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